Your browser doesn't support javascript.
loading
Locus-Specific DNA Methylation Editing in Melanoma Cell Lines Using a CRISPR-Based System.
Smith, Jim; Banerjee, Rakesh; Waly, Reema; Urbano, Arthur; Gimenez, Gregory; Day, Robert; Eccles, Michael R; Weeks, Robert J; Chatterjee, Aniruddha.
Afiliação
  • Smith J; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
  • Banerjee R; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
  • Waly R; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
  • Urbano A; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
  • Gimenez G; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
  • Day R; Department of Biochemistry, Division of Health Sciences, University of Otago, Dunedin 9054, New Zealand.
  • Eccles MR; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
  • Weeks RJ; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
  • Chatterjee A; Department of Pathology, Otago Medical School, University of Otago, Dunedin 9054, New Zealand.
Cancers (Basel) ; 13(21)2021 Oct 29.
Article em En | MEDLINE | ID: mdl-34771597
ABSTRACT
DNA methylation is a key epigenetic modification implicated in the pathogenesis of numerous human diseases, including cancer development and metastasis. Gene promoter methylation changes are widely associated with transcriptional deregulation and disease progression. The advent of CRISPR-based technologies has provided a powerful toolkit for locus-specific manipulation of the epigenome. Here, we describe a comprehensive global workflow for the design and application of a dCas9-SunTag-based tool for editing the DNA methylation locus in human melanoma cells alongside protocols for downstream techniques used to evaluate subsequent methylation and gene expression changes in methylation-edited cells. Using transient system delivery, we demonstrate both highly efficacious methylation and demethylation of the EBF3 promoter, which is a putative epigenetic driver of melanoma metastasis, achieving up to a 304.00% gain of methylation and 99.99% relative demethylation, respectively. Furthermore, we employ a novel, targeted screening approach to confirm the minimal off-target activity and high on-target specificity of our designed guide RNA within our target locus.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Nova Zelândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Nova Zelândia